Eliscer Guzman

1.6k total citations · 2 hit papers
28 papers, 1.0k citations indexed

About

Eliscer Guzman is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Eliscer Guzman has authored 28 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Surgery, 11 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Eliscer Guzman's work include Lipoproteins and Cardiovascular Health (19 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (9 papers) and Pharmaceutical Economics and Policy (6 papers). Eliscer Guzman is often cited by papers focused on Lipoproteins and Cardiovascular Health (19 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (9 papers) and Pharmaceutical Economics and Policy (6 papers). Eliscer Guzman collaborates with scholars based in United States, Greece and Cyprus. Eliscer Guzman's co-authors include Constantine E. Kosmas, Peter D. Montan, Andreas Sourlas, Delia Silverio, Christina Kostara, E Papakonstantinou, Evangelia Papakonstantinou, Andreas P. Niarchos, Mario J. García and George L. Bakris and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Molecular Sciences and Current Medicinal Chemistry.

In The Last Decade

Eliscer Guzman

28 papers receiving 994 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Insulin resistance and cardiovascular disease

2023 170 citations Constantine E. Kosmas, Christina Kostara et al. Journal of International Medical Research profile →
The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease

2023 126 citations Constantine E. Kosmas, E Papakonstantinou et al. Diagnostics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eliscer Guzman United States	17	374	337	256	194	183	28	1.0k
Robert S. Rosenson United States	13	525 1.4×	368 1.1×	359 1.4×	129 0.7×	139 0.8×	26	961
Roberto Scicali Italy	22	350 0.9×	474 1.4×	264 1.0×	228 1.2×	339 1.9×	51	1.2k
Douglas Kling United States	13	596 1.6×	368 1.1×	350 1.4×	207 1.1×	166 0.9×	36	1.3k
Brian T. Steffen United States	19	613 1.6×	315 0.9×	386 1.5×	147 0.8×	140 0.8×	47	1.2k
Christina Kostara Greece	19	334 0.9×	417 1.2×	213 0.8×	264 1.4×	266 1.5×	52	1.3k
Sephy Philip United States	18	569 1.5×	557 1.7×	367 1.4×	120 0.6×	125 0.7×	57	1.1k
Fotios Barkas Greece	20	336 0.9×	284 0.8×	167 0.7×	139 0.7×	115 0.6×	100	1.0k
Marcin Barylski Poland	16	308 0.8×	207 0.6×	451 1.8×	122 0.6×	149 0.8×	80	1.1k
Elisenda Climent Spain	16	434 1.2×	182 0.5×	154 0.6×	132 0.7×	95 0.5×	59	790
Christos V. Rizos Greece	19	392 1.0×	601 1.8×	165 0.6×	375 1.9×	181 1.0×	42	1.3k

Countries citing papers authored by Eliscer Guzman

Since Specialization

Citations

This map shows the geographic impact of Eliscer Guzman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eliscer Guzman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eliscer Guzman more than expected).

Fields of papers citing papers by Eliscer Guzman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eliscer Guzman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eliscer Guzman. The network helps show where Eliscer Guzman may publish in the future.

Co-authorship network of co-authors of Eliscer Guzman

This figure shows the co-authorship network connecting the top 25 collaborators of Eliscer Guzman. A scholar is included among the top collaborators of Eliscer Guzman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eliscer Guzman. Eliscer Guzman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kosmas, Constantine E., et al.. (2023). Insulin resistance and cardiovascular disease. Journal of International Medical Research. 51(3). 3639225476–3639225476. 170 indexed citations breakdown →

Kosmas, Constantine E., et al.. (2023). PCSK9 Targeting in the Management of Hypercholesterolaemia. SHILAP Revista de lepidopterología. 87–97. 4 indexed citations

Kosmas, Constantine E., et al.. (2023). Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a). International Journal of Molecular Sciences. 24(17). 13622–13622. 19 indexed citations

Kosmas, Constantine E., et al.. (2023). The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease. Diagnostics. 13(5). 929–929. 126 indexed citations breakdown →

Kosmas, Constantine E., et al.. (2022). Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia. Clinical Pharmacology Advances and Applications. Volume 14. 49–59. 24 indexed citations

Kosmas, Constantine E., et al.. (2021). New and emerging lipid-modifying drugs to lower LDL cholesterol. Drugs in Context. 10. 1–22. 24 indexed citations

Sourlas, Andreas, et al.. (2020). Safety and Tolerability of PCSK9 Inhibitors: Current Insights. SHILAP Revista de lepidopterología. 21 indexed citations

Kosmas, Constantine E., et al.. (2020). <p>Safety and Tolerability of PCSK9 Inhibitors: Current Insights</p>. Clinical Pharmacology Advances and Applications. Volume 12. 191–202. 28 indexed citations

Kosmas, Constantine E., et al.. (2020). <p>Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential</p>. Therapeutics and Clinical Risk Management. Volume 16. 1031–1037. 37 indexed citations

10.

Kosmas, Constantine E., Delia Silverio, Andreas Sourlas, et al.. (2019). Anti-inflammatory therapy for cardiovascular disease. Annals of Translational Medicine. 7(7). 147–147. 49 indexed citations

11.

Montan, Peter D., et al.. (2019). Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Annals of Translational Medicine. 7(16). 393–393. 40 indexed citations

12.

Kosmas, Constantine E., Delia Silverio, Andreas Sourlas, Peter D. Montan, & Eliscer Guzman. (2019). Dysfunctional high-density lipoprotein and atherogenesis. Vessel Plus. 2019. 6 indexed citations

13.

Kosmas, Constantine E., et al.. (2018). Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia. Patient Preference and Adherence. Volume 12. 2263–2266. 25 indexed citations

14.

Kosmas, Constantine E., et al.. (2018). Primary genetic disorders affecting high density lipoprotein (HDL). Drugs in Context. 7. 1–11. 11 indexed citations

15.

Kosmas, Constantine E., Delia Silverio, Andreas Sourlas, Peter D. Montan, & Eliscer Guzman. (2018). Role of spironolactone in the treatment of heart failure with preserved ejection fraction. Annals of Translational Medicine. 6(23). 461–461. 15 indexed citations

16.

Kosmas, Constantine E., et al.. (2017). Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy. Drugs in Context. 6. 1–7. 23 indexed citations

17.

Kosmas, Constantine E., et al.. (2017). Effects of Statins on Cardiovascular Outcomes in Patients With Chronic Kidney Disease. 2017(9). 0–0. 4 indexed citations

18.

Lazich, Ivana, et al.. (2011). Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes Obesity and Metabolism. 14(2). 181–186. 16 indexed citations

19.

Guzman, Eliscer, Narpinder Singh, Ijaz A. Khan, et al.. (2004). Left Bundle Branch Block in Type 2 Diabetes Mellitus: A Sign of Advanced Cardiovascular Involvement. Annals of Noninvasive Electrocardiology. 9(4). 362–365. 12 indexed citations

20.

Guzman, Eliscer, et al.. (1994). Torsades de pointes induced by erythromycin and terfenadine. The American Journal of Emergency Medicine. 12(6). 636–638. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact